Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis

Biochimica et Biophysica Acta - General Subjects

Volumn 1760, Issue 4, 2006, Pages 669-677

  Holland, M ^a   Yagi, H ^b,c   Takahashi, N ^b,c,d   Kato, K ^b,c,d   Savage, C O S ^a,e   Goodall, D M ^a   Jefferis, R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d GLYENCE Co Ltd   (Japan)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

IgG, ANCA; IgG Fc IgG Fab glycosylation; Post translational modifications

Indexed keywords

IMMUNOGLOBULIN G; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; MICROSCOPIC POLYANGIITIS; MOLECULAR DYNAMICS; PLASMA CELL; PRIORITY JOURNAL; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CASE-CONTROL STUDIES; GALACTOSE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; OLIGOSACCHARIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; VASCULITIS;

EID: 33646093725     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2005.11.021     Document Type: Article

References (41)

1. http://www.us.expasy.org/sprot/hpi/
2. O'Donovan C., Apweiler R., and Bairoch A. The human proteomics initiative (HPI). Trends Biotechnol. 19 (2001) 178-181
3. Bauman M., and Meri S. Techniques for studying protein heterogeneity and post-translational modifications. Expert Rev. Proteomics 2 (2004) 207-217
4. Wong C.H. Protein glycosylation: new challenges and opportunities. J. Org. Chem. 70 (2005) 4219-4225
5. Freeze H.H. Human disorders in N-glycosylation and animal models. Biochim. Biophys Acta 1573 (2002) 388-393
6. Butler M., Quelhas D., Critchley A.J., Carchon H., Hebestreit H.F., Hibbet R.G., Vilarinho L., Teles E., Matthijs G., E.Schollen P., Argibay D.J., Harvey R.A., and Dwek P.M. Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology 13 (2003) 601-622
7. Parekh R.B., Dwek R.A., Sutton B.J., Fernandes D.L., Leung A., Stanworth D., Rademacher T.W., Mizuochi T., Taniguchi T., Matsuta K., Takeuchi F., Nagano Y., Miyamoto T., and Kobata A. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316 (1985) 452-457
8. Youings A., Chang S.C., Dwek R.A., and Scragg I.G. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem. J. 314 (1996) 621-630
9. Axford J.S., Cunnane G., Fitzgerald O., Bresnihan B., and Frears E.R. Rheumatic disease differentiation using immunoglobulin G sugar printing by high density electrophoresis. J. Rheumatol. 12 (2003) 2540-2546
10. Takahashi N., Ishii I., Ishihara H., Mori M., Tejima S., Jefferis R., Endo S., and Arata Y. Comparative structural study of the N-linked oligosaccharides of human normal and pathological immunoglobulin G. Biochemistry 26 (1987) 1137-1144
11. Gu J., Kondo A., Okamoto N., and Wada Y. Oligosaccharide structures of immunoglobulin G from two patients with carbohydrate-deficient glycoprotein syndrome. Glycosyl. Dis. 1 (1994) 247-252
12. Ito K., Takahashi N., and Hirayama M. Abnormalities in the oligosaccharide moieties of immunolglobulin G in patients with mytonic dystrophy. J. Clin. Biochem. Nutr. 14 (1993) 61-69
13. Holland M., K.Takada T., Okumoto N., Takahashi K., Kato D., Adu A., Ben-Smith L., Harper C.O.S., and Savage R. Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. Clin. Exp. Immunol. 129 (2002) 183-190
14. Poland D.C., Vallejo J.J., Niedden H.W., Nijmeyer R., Calafat J., Hack C.E., Van Het HofB., and van Dijk W. Activated human PMN synthesize and release a strongly fucosylated glycoform of {alpha}1-acid glycoprotein, which is transiently deposited in human myocardial infarction. J. Leukocyte Biol. 78 (2005) 453-461
15. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21 (2005) 11-16
16. Gomord V., Chamberlain P., Jefferis R., and Foye L. The production of biopharmaceuticals in plants: Problems, solutions and opportunities. Trends Biotechnol. 23 11 (2005) 559-565
17. Umana P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17 (1999) 176-180
18. Davies J., Jiang L., LaBarre M.J., Anderson D., and Reff M. Expression of GTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies of altered glycoforms leads to an increase in ADCC thro′ higher affinity for FcRIII. Biotechnol. Bioeng. 74 (2001) 288-294
19. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., and Presta L.G. Lack of fucose on human IgG1 N-Linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002) 26733-26740
20. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., and Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
21. Hadley A.G., Zupanska B., Kumpel B.M., Pilkington C., Griffiths H.L., Leader K.A., Jones J., Booker D.J., and Sokol R.J. The glycosylation of red cell autoantibodies affects their functional activity in vitro. Br. J. Haematol. 91 (1995) 587-594
22. Van den Nieuwenhof I.M., Koistinen H., Easton R.L., Koistinen R., Kamarainen M., Morris H.R., Van Die I., Seppala M., Dell A., and Van den Eijnden D.H. Recombinant glycodelin carrying the same type of glycan structures as contraceptive glycodelin-A can be produced in human kidney 293 cells but not in chinese hamster ovary cells. Eur. J. Biochem. 267 (2000) 4753-4762
23. Raju T.S., Briggs J.B., Borge S.M., and Jones A.J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10 (2000) 477-486
24. Sinclair A.M., and Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94 (2005) 1626-1635
25. Smalling R., Foot M., Molineux G., Swanson S.J., and Elliott S. Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge. Biotechnol. Annu. Rev. 10 (2004) 237-250
26. Matsuda K., Yamaguchi Y., Kato K., Takahashi N., and Arat Y. Pairing of oligosaccharides in the Fc region of immunoglobulin G. FEBS Lett. 473 (2000) 349-357
27. Gala F.A., and Morrison S.L. V region carbohydrate and antibody expression. J. Immunol. 172 (2004) 5489-5494
28. Tachibana H., Seki K., and Murakami H. Identification of hybrid-type carbohydrate chains on the light chain of human monoclonal antibody specific to lung adenocarcinoma. Biochim. Biophys. Acta 1182 (1993) 257-263
29. Khurana S., Raghunathan V., and Salunke D.M. The variable domain glycosylation in a monoclonal antibody specific to GnRH modulates antigen binding. Biochem. Biophys. Res. Commun. 234 (1997) 465-469
30. Zhu D., Ottensmeier C.H., Du M.Q., McCarthy H., and Stevenson F.K. Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. Br. J. Haematol. 120 (2003) 217-222
31. http://www.bioch.ox.ac.uk/glycob/posters/catherine_radcliffe_jenner_2004.pdf
32. Jefferis R., Lund J., and Pound J.D. IgG-Fc mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 163 (1998) 59-76
33. Jefferis R., and Lund J. Interaction sites on human IgG-Fc for FcγR: current models. Immunol. Lett. 82 (2002) 57-65
34. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., Hagen E.C., Hoffman G.S., Hunder G.G., Kallenberg C.G.M., McCluskey R.T., Sinico R.A., Rees A.J., Waldherr R., and Wiik A. Nomenclature of systemic vasculitides. Arthritis Rheum. 37 (1994) 187-192
35. Jefferis R., Lund J., Muzutani H., Nakagawa H., Kawazoe Y., Arata Y., and Takahashi N. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem. J. 268 (1990) 529-537
36. Takahash N., Nakagawa H., Fujikawa K., Kawamura Y., and Tomiya N. Three-dimensional elution mapping of pyridylaminated N-linked neutral and sialyl oligosaccharides. Anal. Biochem. 226 (1995) 139-146
37. Yagi H., Takahashi N., Yamaguchi Y., Kimura N., Uchimura K., Kannagi R., and Kato K. Development of structural analysis of sulfated N-glycans by multi-dimensional high performance liquid chromatography mapping methods. Glycobiology 15 10 (2005) 1051-1060
38. Yagi H., Takahashi N., Yamaguchi Y., and Kato K. Temperature-dependent isologous Fab-Fab interaction that mediates cryocrystallization of a monoclonal immunoglobulin G. Mol. Immunol. 41 (2004) 1211-1215
39. Takahashi N., and Kato K. GALAXY (Glycoanalysis by the Three Axes of MS and Chromatography): a web application that assists structural analyses of N-glycans. Trends Glycosci. Glycotechnol. 15 (2003) 235-251
40. Axford J.S. Decreased B-cell galactosyltransferase activity in rheumatoid arthritis. Br. J. Rheumatol. 27 Suppl. 2 (1988) 170
41. Delves P.J., Axford J.S., Alavi-Sadrieh A., Lydyard P.M., MacKenzie L., Smith M.D., and Kidd V.J. Polymorphism and expression of the galactosyltransferase-associated protein kinase gene in normal individuals and galactosylation-defective rheumatoid arthritis patients. Arthritis Rheum. 11 (1990) 1655-1664